Shuttle Pharma names Timothy Lorber as CFO; Vander Hoek shifts to VP Regulatory

Shuttle Pharmaceuticals Holdings, Inc.

Timothy Lorber, CPA with 40+ years experience, appointed CFO; part-time until Sept 9, 2024, then full-time from Sept 10, 2024.
Lorber receives $227k annual base salary; 227,635 RSUs vesting over 3 years; eligible for up to $72k milestone bonus.
Current CFO Michael Vander Hoek transitions to full-time Vice President, Regulatory concurrent with Lorber's full-time appointment.
Vander Hoek had served as both CFO and VP Regulatory for past four years; will now focus on regulatory matters for Phase 2 trial.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy J. Lorber

Chief Financial Officer

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2024-06-13
Filed: June 18, 2024, 7:59 PM ET

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

Role change

Michael Vander Hoek

Vice President, Regulatory

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2024-09-10
Successor: Timothy J. Lorber
Filed: June 18, 2024, 7:59 PM ET

The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy J. Lorber was appointed as Chief Financial Officer at Shuttle Pharmaceuticals Holdings, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Vander Hoek changed role as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..

Action: transitioning
Role: Vice President, Regulatory

Exact text from the filing

The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.

View on SEC.gov

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-024224

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.